---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022277"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:14:28.683398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B

## Summary
- Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.
- R&D expense $1.2M (down 56% YoY) due to grant funding; G&A $2.5M (up 25% YoY) on commercial readiness.
- DARE to PLAY Sildenafil Cream on track for initial Rx fulfillment Dec 2025 via 503B compounding (near-term revenue).
- Positive DSMB recommendation for Ovaprene Phase 3 study; enrollment continues.
- Received $6M (Jul) and $4M (Oct) grant installments for DARE-LARC1; $3.6M expected for DARE-NHC in Nov 2025.

## SEC filing metadata
- accession: 0001493152-25-022277
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/0001493152-25-022277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022277
- JSON: https://secwatch.observer/filing/0001493152-25-022277.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.